Aclacinomycin A (hydrochloride)

Aclacinomycin A (Aclarubicin) hydrochloride is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A hydrochloride is an inhibitor of topoisomerase I and II. Aclacinomycin A hydrochloride inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A hydrochloride might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis[1][2][3].

Product Specifications

CAS Number

[75443-99-1]

Product Name Alternative

Aclarubicin (hydrochloride)

UNSPSC

12352005

Hazard Statement

H301-H311-H331

Target

Antibiotic; DNA/RNA Synthesis; Proteasome; Topoisomerase

Type

Natural Products

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Aclacinomycin_A_hydrochloride.html

Purity

95.16

Solubility

10 mM in H2O|DMSO : ≥ 125 mg/mL

Smiles

O=C([C@@H]1C2=CC(C(C3=CC=CC(O)=C43)=O)=C(C4=O)C(O)=C2[C@@H](O[C@@](O[C@@H](C)[C@H]5O[C@@](O[C@@H](C)[C@H]6O[C@](CCC7=O)([H])O[C@H]7C)([H])C[C@@H]6O)([H])C[C@@H]5N(C)C)C[C@]1(O)CC)OC.Cl

Molecular Formula

C42H54ClNO15

Molecular Weight

848.33

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P361+P364-P403+P233-P405-P501

References & Citations

[1]Isoe T, et al. Inhibition of different steps of the ubiquitin system by CDDP and aclarubicin. Biochim Biophys Acta. 1992 Sep 15;1117 (2) :131-5.|[2]Hajji N, et al. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583 (1) :26-35.|[3]Iihoshi H, et al. Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol Lett. 2017 Aug 5;277:109-114.|[4]Hori S, et al. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity. Gan. 1977 Oct;68 (5) :685-90.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Natural Products

Clinical Information

Launched

Isoform

Topo I; Topo II

Citation 01

Bioengineered. 2022 Feb;13 (2) :2207-2216.|bioRxiv. 2023 Jan 13.|Int J Hyperthermia. 2022;39 (1) :998-1009.|Biomolecules. 2025 Jul 6.|Patent. US20250129329A1.